Identification of two new translocations that disrupt the AML1 gene

Kathleen Richkind, Robert Hromas, C. Lytle, D. Crenshaw, J. Velasco, S. Roherty, Jayanthi Srinivasiah, Marileila Varella-Garcia

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


The AML1 gene, located at chromosome 21q22, encodes a component (CBFα2) of a heterodimeric transcription factor complex termed core binding factor (CBF), which binds to DNA and activates gene expression. Chromosomal rearrangements may lead to disruption of this gene and development of acute leukemia. Twelve AML1 translocations have been identified to date, and include sites on chromosomes 1, 2, 3, 5, 8, 12, 14, 15, 16, 17, 18, and 19. Here we report two new translocations involving AML1 in acute myeloid leukemia, in which the disruption of the AML1 gene was documented by GTG banding cytogenetic studies and metaphase and interphase FISH analysis. These chromosomal breakpoints identified as harboring new fusion partners for AML1 are at 2p11.2 and 20q13.1. The two patients in who these translocation were identified were elderly males with newly diagnosed AML. These patients shared the same poor outcomes reported for other rare AML1 translocations. (C) 2000 Elsevier Scinece Inc.

Original languageEnglish (US)
Pages (from-to)141-143
Number of pages3
JournalCancer Genetics and Cytogenetics
Issue number2
StatePublished - Oct 15 2000
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Identification of two new translocations that disrupt the AML1 gene'. Together they form a unique fingerprint.

Cite this